Digisonics Promotes Tony Fossile To Director Of Sales

Digisonics, a leading provider of PACS and Structured Reporting Software Solutions for cardiology, OB/GYN and radiology studies, today announced that Tony Fossile has been promoted to Director of Sales.

Tony Fossile's promotion to Director of Sales will extend his responsibilities to Digisonics' national sales force, leading them to source, negotiate and secure new business. Fossile's experience in healthcare spans four decades, starting in clinical and research neurophysiology, then as a key member of a start-up X-ray imaging team at the forefront of robotic and digital imaging technologies in the late 80's. He entered into the Cardiovascular Information System market in the mid 90's working for Lockheed Martin/L3 Communications on collaborative efforts with both GE Medical and Heartlab. Fossile joined Heartlab as a National Sales Specialist and eventually became the VP of Sales for the Eastern Region. Not long after the AGFA acquisition of Heartlab, he joined McKesson, and in his second year earned Top Performer in Cardiology Sales. Three short years ago, Fossile joined Digisonics as Regional Sales Manager for the East before being named as Director of Sales - East, last year.

"Digisonics had been courting Tony Fossile for a long-time, and was very pleased to have him join our team a few years ago," said James Devlin, President. "He is one of the most respected and experienced CVIS, PACS and Structured Reporting people in the industry today and he will continue to have a terrific impact on Digisonics' success."

Suggested Articles

EQRx is adding a pair of PD-1/PD-L1 meds to its pipeline through a deal with CStone worth $150 million upfront but could net the latter $1.15 billion.

All eyes are on Pfizer’s COVID-19 vaccine work, but the Big Pharma has today quietly culled two midstage trials and one phase 1 test.

All subjects had lower extremity weakness after receiving antisense oligonucleotide GTX-102, leading Ultragenyx to pause the study.